期刊文献+

反相高效液相色谱法检测人血浆伊马替尼的浓度 被引量:5

Determination of imatinib in human plasma by RP- HPLC
原文传递
导出
摘要 目的建立人血浆伊马替尼检测的高效液相色谱方法。方法色谱柱为ZORBAX XDB-C18(150 mm×4.6 mm,5μm);以乙腈-0.1%三氟乙酸-水(20∶40∶40)为流动相,流速为1.0 mL·min-1;检测波长为282 nm,柱温为35℃,以加替沙星为内标,血浆经高氯酸沉淀后检测。结果血浆伊马替尼浓度在0.10~10.00 mg·L-1范围内线性关系良好(r=0.999 7);低、中、高3个浓度(0.25,2.50,7.50 mg·L-1)的日内RSD分别为4.02%,3.64%和2.54%,日间RSD分别为5.08%,3.25%和2.48%;相对回收率分别为(99.76±5.07)%,(101.08±328)%和(100.15±2.48)%。结论该方法简便、快速、准确,适用于伊马替尼临床治疗药物监测及其药代动力学研究。 Objective To develop a HPLC method for the determination of imatinib in human plasma. Methods The analytical column was packed with ZORBAX XDB -C18. A mixture of acetonitrile-0. 1% trif- luoroacetic acid-water(20:40:40)was used as the mobile phase with the flow rate at 1.0 mL·min^-1 The detection wavelength was 282 nm. The column temperature was 35 ℃. Gatifloxacin was used as internal standard, plasma was precipited by perchloric acid and imatinib was detected. Results Excellent liner relationship was obtained from the range of 0. 10 mg·L^-1 to 10.00mg·L^-1 ( r = 0. 999 7 ). The intra - day RSD were 4.02%,3.64%,2.54% and inter - day RSD were 5.08%, 3.25% , 2.48% at three concentrations (0. 25,2. 50,7.50mg·L^-1), the relative recovery rates were (99.76 ± 5.07 )%, ( 101.08± 3.28 )% and ( 100. 15 ± 2. 48 ) %, respectively. Conclusion The method is simple, rapid, accurate and could be suitable for imatinib clinical therapeutic drug monitoring and its pharmacokinetics study.
出处 《中国临床药理学杂志》 CAS CSCD 北大核心 2013年第10期777-779,共3页 The Chinese Journal of Clinical Pharmacology
关键词 伊马替尼 高效液相色谱法 血浆浓度 imatinib HPLC plasma concentration
  • 相关文献

参考文献8

二级参考文献51

  • 1Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res, 2002, 8: 935-942.
  • 2Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment. Blood, 2008, 111: 1039-1043.
  • 3Palandri F, Castagnetti F, Alimena G, et al. The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up. Haematologica, 2009, 94: 205-212.
  • 4Druker BJ, Guilhot F, O" Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med, 2006, 355: 2408-2417.
  • 5Bianchini M, De Brasi C, Gargallo P, et al. Specific assessment of BCR-ABL transcript overexpression and imatinib resistance in chronic myeloid leukemia patients. Eur J Haematol, 2008.
  • 6Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med, 2001, 344: 1031-1037.
  • 7Deininger MW, Goldman JM, Lydon N, et al. The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL- positive cells. Blood, 1997, 90: 3691-3698.
  • 8Colombat M, Fort M P, Chollet C, et al. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment. Haematologica, 2006, 91: 162-168.
  • 9Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 2007, 109: 3496-3499.
  • 10Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmaeokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood, 2008, 111: 4022-4028.

共引文献35

同被引文献24

  • 1XIAO X, LIU Y, QI c, et al. Neuroprotection and enhanced neuro- genesis by tetramethylpyrazine in adult rat brain after focal ischemia [J]. Neurol Res, 2010, 32(5) :547 -555.
  • 2YANG J, LI J, LU J, et al. Synergistic protective effect of astragalo- side IV - tetramethyl pyrazine against cerebral ischemic - reperfusion injury induced by transient focal ischemia [ J ]. J Ethnopharmacol, 2012, 140(1) :64 -72.
  • 3LV L, JIANG S S, XU J, et al. Protective effect of ligustrazine against myocardial ischaemia reperfusion in rats : the role of endothe- lial nitric oxide synthase [ J ]. Clin Exp Pharmacol Physiol, 2012, 39(1) :20 -27.
  • 4ZENG M, ZHANG J, YANG Y, et al. An automated dual - gradient liquid chromatography - MS/MS method for the simultaneous deter- mination of ferulic acid, ligustrazine and ligustilide in rat plasma and its application to a pharmacokinetic study [ J ]. J Pharm Biomed Analy, 2014, 88(1) : 354 -363.
  • 5TENG J F, MABASA V H, ENSOM M H. The role of therapeutic drug monitoring of imatinibin patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors [ J ]. Ther Drug Monit ,2012,34( 1 ) :85 - 97.
  • 6DE FRANCIA S, D AVOLIO A, DE MARTINO F, et al. New HPLC - MS method for the simultaneous quantification of the antileu- kemia drugs imatinib, dasatinib, and nilotinib in human plasma[ J ]. J Chromatogr B Analyt Technol Biomed Life Sci, 2009,877 ( 18 - 19) :1721 - 1726.
  • 7王利胜,袁爱贤,韩坚,陈秀娟,郭琦.HPLC法测定川芎嗪在小鼠血浆、脑、肝中的含量[J].中国药房,2008,19(9):654-656. 被引量:11
  • 8龙庆林,房殿春.胃肠道间质瘤发生的分子机制以及伊马替尼治疗研究进展[J].胃肠病学,2008,13(8):452-455. 被引量:5
  • 9钟健生(综述),孟凡义(审校).伊马替尼血药浓度检测的意义[J].白血病.淋巴瘤,2010,19(1):61-64. 被引量:7
  • 10张华峰,戴博,宋青,王鑫.高效液相色谱法测定人血浆中伏立康唑含量[J].解放军药学学报,2010,26(5):446-448. 被引量:4

引证文献5

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部